For example, siRNAs targeting VEGF, encapsulated in LNPs decorated with anti-EGFR antibodies, selectively silence VEGF expression in EGFR+ esophageal cancer, inhibiting angiogenesis and tumor growth while reducing off-target effects. This evidence concerns the gene EGFR and esophageal cancer.